INTRODUCTION AND OBJECTIVES: Chronic ischemia induced by pelvic arterial occlusive disease plays a key role in the development of lower urinary tract symptom. However, the mechanisms underlying the changes in bladder function caused by chronic ischemia are not completely known. On the other hand, it is well known that uroplakin (UP) Ia, UP Ib, UP II, and UP III are critical to normal urothelial barrier function. Recent studies suggested that UPs play a role in homeostasis in the urinary bladder mucosa and UPs defects lead to abnormal voiding patterns. The aim of the study is to investigate the effect of arterial occlusive disease related chronic ischemia on UPs in the bladder by using a rat model of chronic bladder ischemia.
INTRODUCTION AND OBJECTIVES: Chronic ischemia induced by pelvic arterial occlusive disease plays a key role in the development of lower urinary tract symptom. However, the mechanisms underlying the changes in bladder function caused by chronic ischemia are not completely known. On the other hand, it is well known that uroplakin (UP) Ia, UP Ib, UP II, and UP III are critical to normal urothelial barrier function. Recent studies suggested that UPs play a role in homeostasis in the urinary bladder mucosa and UPs defects lead to abnormal voiding patterns. The aim of the study is to investigate the effect of arterial occlusive disease related chronic ischemia on UPs in the bladder by using a rat model of chronic bladder ischemia.
METHODS: Adult Sprague-Dawley male rats (16-week old) were divided into two groups (chronic bladder ischemia: CBI, control). The CBI group underwent balloon endothelial injury of the bilateral iliac arteries and received a 2 % cholesterol diet for 8 weeks to induce arterial occlusive disease related chronic ischemia (n¼10). The control group received a regular diet for 8 weeks (n¼10). After monitoring their urine output for 24 hours, the bladders were harvested for pharmacological and histological examinations. The bladder was processed for immunohistochemical staining of UPs. And we used western blotting to measure the expression of UP Ia, UP Ib, UP II UP III and HIF1a, which was oxidative stress marker, in the bladder of this rat model. All values were expressed as mean AE standard deviation. P-values of <0.05 were considered to be statistically significant.
RESULTS: In the metabolic cage studies showed the mean voided volume and maximum voided volume were significantly smaller in the CBI group than in the control group (Control vs CBI, mean voided volume: 1.46 AE 0.33 ml vs 1.01 AE0.21 ml; P¼0.001, maximum voided volume: 2.62 AE 0.60 ml vs 2.01 AE 0.41 ml; P¼0.023). The western blot analysis showed the expression of HIF1a was significantly increased, and UP II expression was significantly decreased (P¼0.011), in the CBI group as compared with the control group. In the immunohistochemical staining, UP II positive cells are located mostly on urothelium. The percentage of UP II positive cells was significantly lower in the CBI group than in the control group (Control vs CBI: 92.1 AE 0.1 % vs 63.0 AE 0.11 %; P<0.001).
CONCLUSIONS: Our results suggest that pelvic arterial occlusive disease causes uroplakin II deficiency in the bladder of this rat model. It is possible that uroplakin II deficiency is one cause of chronic ischemia-related bladder dysfunction.
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MP38-17 METABOLOMIC ANALYSIS OF CANDIDATE URINARY MARKERS OF OVERACTIVE BLADDER SYNDROME IN AN AGING FEMALE POPULATION
Abubakr Mossa*, Samer Shamout, Philippe Cammisotto, Lysanne Campeau, Montreal, Canada INTRODUCTION AND OBJECTIVES: Overactive bladder syndrome (OAB) shows increasing prevalence with aging. OAB is found in association with metabolic syndrome, yet the mechanism is not clear. Urine metabolome is a useful tool to diagnose metabolic alterations which may, by local effect, affect bladder physiology. The aim of this study is to identify specific metabolic markers of OAB using urine metabolomics of an aging female population.
METHODS: Forty female patients (50-80 years old), 20 OAB and 20 controls, underwent clinical evaluation and LUTS assessment with validated questionnaires (OABSS, ICIQ-SF, IIQ-7). Participants completed a 3-day voiding diary and blood sampling. Early morning urine samples were collected for urine culture and metabolomic analysis. Urinary metabolomics were analyzed by gas chromatographymass spectrometry (GC-MS) and results were normalized to creatinine.
RESULTS: Demographics analysis did not show significant differences except for a higher mean age in OAB group reflecting the natural higher prevalence in the elderly. Laboratory blood analyses results indicated a potential tendency of OAB group to have dyslipidemia and worse glycemic indices with significantly higher serum urea, creatinine and eGFR (Table 1) . Table ( 2) illustrates metabolites with significant difference between the two groups, out of 60 analyzed. Correlation showed that 2-hydroxyisobutyric, methylsuccinic and fumaric acid, among other metabolites, correlate significantly with the severity of symptoms assessed by questionnaires.
CONCLUSIONS: OAB patients showed increased serum triglycerides, glycemic indices, urea and creatinine as well as higher urinary levels of protein and lipids metabolites and energy intermediates that correlated significantly with the severity of the OAB symptoms. This pilot study can help to identify potential new biological markers of OAB and link them with markers of metabolic syndrome.
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